SBC Medical Group (NASDAQ:SBC) Releases Earnings Results, Misses Expectations By $0.02 EPS

SBC Medical Group (NASDAQ:SBC) issued its quarterly earnings results on Thursday. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.02), FiscalAI reports. The company had revenue of $49.19 million for the quarter, compared to the consensus estimate of $45.37 million. SBC Medical Group had a net margin of 27.99% and a return on equity of 18.81%.

Here are the key takeaways from SBC Medical Group’s conference call:

• Positive Sentiment: SBC reported strong second-quarter results, with revenue up 13% to $49 million, adjusted EBITDA up 32% to $20 million, and a 41% margin. Clinic locations increased to 287, visits rose 10%, and average spend per visit increased 9%.
• Positive Sentiment: Management said domestic aesthetic medicine has re-accelerated after marketing, pricing, and treatment reforms, with same-clinic revenue up 6% and first-half transaction value up 19%. It expects a more favorable competitive environment as the pace of new clinic openings slows.
• Positive Sentiment: AI is being deployed across customer service, marketing, call-center operations, site selection, and employee training, with management targeting higher clinic revenue and greater operating efficiency. Planned service-fee increases are expected to add roughly JPY 15 million annually, with most of the contribution flowing to profit.
• Positive Sentiment: The company is broadening beyond aesthetics through non-aesthetic healthcare, international expansion, and new longevity offerings. It is targeting 1,000 clinics by 2035, while pursuing asset-light expansion in Southeast Asia and further growth with OrangeTwist in the U.S.
• Negative Sentiment: A weaker Japanese yen remains a headwind because most operations are yen-denominated, while competition in Japan has recently been intense. SG&A also increased, although management attributed much of the rise to one-time costs related to the secondary offering.

SBC Medical Group Stock Up 14.7%

SBC Medical Group stock opened at $3.66 on Friday. The stock has a fifty day moving average of $3.08 and a 200 day moving average of $3.56. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.78 and a current ratio of 3.82. The stock has a market cap of $375.43 million, a PE ratio of 7.79 and a beta of 0.59. SBC Medical Group has a one year low of $2.78 and a one year high of $5.07.

Wall Street Analyst Weigh In

A number of research firms have recently commented on SBC. Wall Street Zen upgraded shares of SBC Medical Group from a “hold” rating to a “buy” rating in a report on Saturday. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of SBC Medical Group in a research report on Thursday. Finally, Weiss Ratings downgraded SBC Medical Group from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $8.50.

Trending Headlines about SBC Medical Group

Here are the key news stories impacting SBC Medical Group this week:

• Positive Sentiment: Strong second-quarter growth: SBC reported revenue of $49.19 million, up 13% year over year and ahead of the $45.37 million analyst estimate. Net income jumped 335%, while adjusted EBITDA increased 32%, indicating improved profitability following the company’s restructuring. SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Ambitious clinic expansion: Management outlined a goal of reaching 1,000 clinics by 2035 and identified as much as $15 million in potential annual fee revenue. The targets support the company’s long-term growth narrative and could improve recurring revenue if executed successfully. SBC targets 1,000 clinics by 2035 while outlining $15M annual fee upside
• Positive Sentiment: Analyst confidence: BTIG Research reaffirmed its “buy” rating and set an $8.00 price target, implying substantial upside from the recent trading level. BTIG Research rating information
• Neutral Sentiment: Key earnings caveat: Quarterly EPS was $0.10, below the $0.12 consensus estimate. However, the revenue beat and sharp increases in net income and EBITDA may be receiving greater attention from investors.
• Negative Sentiment: Execution risk remains: The 1,000-clinic objective extends through 2035, so achieving the projected fee opportunity will depend on sustained expansion, successful integration and continued profitability improvements. SBC Q2 2026 earnings call transcript

Institutional Trading of SBC Medical Group

Institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. purchased a new stake in SBC Medical Group in the fourth quarter worth $49,000. Russell Investments Group Ltd. boosted its stake in shares of SBC Medical Group by 292.0% during the fourth quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company’s stock valued at $51,000 after purchasing an additional 8,771 shares during the period. Nuveen LLC purchased a new stake in shares of SBC Medical Group during the fourth quarter valued at $53,000. Wells Fargo & Company MN grew its holdings in shares of SBC Medical Group by 195.1% in the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company’s stock worth $54,000 after purchasing an additional 8,348 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of SBC Medical Group in the second quarter worth about $64,000. 60.82% of the stock is currently owned by institutional investors.

SBC Medical Group Company Profile

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.